A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors (NCT06997029)
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Providence St. Jude Medical Center — Fullerton, California
- Marin Cancer Care — Greenbrae, California
- Moores Cancer Center — La Jolla, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Local Institution - 0008 — Aurora, Colorado
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health-Cancer Institute — New Hyde Park, New York
- Local Institution - 0011 — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- START Dallas Fort Worth — Fort Worth, Texas
- NEXT Oncology — San Antonio, Texas
- Odense Universitetshospital — Odense, Region Syddanmark
- Copenhagen University Hospital — Copenhagen,
- National Cancer Center Hospital East — Kashiwa, Chiba
- Kansai Medical University Hospital — Hirakata, Osaka
- National Cancer Center Hospital — Chuo-ku, Tokyo
- The Cancer Institute Hospital of JFCR — Koto-ku, Tokyo
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.